Gastric Cancer

Surgical palliation improved quality of live and solid food intake in patients with certain types of gastric cancer, according to a recent study.

A recent study found that Opdivo improves survival in patients with gastric or gastroesophageal junction (GEJ) cancer.

The JAVELIN trial showed that many patients with gastric cancer could benefit from immunotherapy.

Since chemotherapy can offer only a limited amount of help in fighting gastroesophageal cancers, a growing emphasis on prevention — as well as on the development of immunotherapies — will be extremely important.

For about 20 percent of patients with advanced gastric cancer, tumors overproduce a receptor protein called HER2.

In the oncology world, gastrointestinal cancers may be the next in line to realize the promise of immunotherapy.

Diagnoses in younger people and two causative infections are providing clues about how to better prevent and treat gastric cancer.

The decision to remove one's stomach may be difficult, but it can also be life-saving.

Results from new clinical trials signal a role for the immunotherapy Opdivo in the treatment of gastric cancer and heavily pretreated esophageal cancer.

I will be out on the street in New York City on November 1 to cheer on James Blake.

Moving back into the light.

The medical team had reached some conclusions.

This is how I became hospital property.

Twenty strokes signaled that there was trouble, though no one would have suspected a tumor.

It is now well recognized that the presence of a molecular abnormality shown to be actionable in one tumor type may be highly clinically relevant in other malignancies.

In the hopes of recreating the successes achieved in other solid malignancies, researchers have evaluated many types of targeted therapy for the treatment of advanced gastric cancer.

Debbie Zelman is the founder and president of Debbie's Dream Foundation: Curing Stomach Cancer, a nonprofit organization that is dedicated to educating and supporting patients and their families.

Among patients with metastatic gastric cancer treated with the PD-1 inhibitor Keytruda, the agent showed promising activity, according to updated findings from the KEYNOTE-012 study presented at the Gastrointestinal Cancers Symposium.

Why is November not named an "awareness month?" Because stomach cancer isn't only about awareness.

The FDA approves Cyramza (ramucirumab) in combination with paclitaxel for the treatment of advanced gastric cancer or GEJ adenocarcinoma.

The latest in cancer prevention, diagnosis & treatment

A study published last December showed foods found in traditional diets in Greece, Italy, and other Mediterranean countries, lowered the risk of gastric cancer by 33 percent.

A breast cancer drug delivers a heavy blow to certain stomach cancers.

Chef Hans Rueffert, 37, helps others understand that it's quality, not quantity, of food that matters.

News from the 2009 annual meeting of the American Society of Clinical Oncology.

The breast cancer drug Herceptin (trastuzumab) extends survival in certain gastric cancer patients by almost three months, according to a phase III international study.

Treatment updates from the 2009 ASCO Gastrointestinal Cancers Symposium.